Research programme: immunological cancer therapies - IDM Pharma
Latest Information Update: 22 Feb 2010
At a glance
- Originator IDM Pharma
- Developer Pierre Fabre; Takeda America Holdings
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
- 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
- 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma